A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Urelumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Jan 2018 Planned end date changed from 18 Jun 2018 to 18 Jun 2019.
- 31 Jan 2018 Planned primary completion date changed from 17 Jun 2018 to 17 Jun 2019.
- 27 Mar 2017 Status changed to recruiting.